Jim Simons Enlivex Therapeutics Ltd. Transaction History
Renaissance Technologies LLC
- $63.4 Billion
- Q4 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Renaissance Technologies LLC holds 158,992 shares of ENLV stock, worth $190,790. This represents 0.0% of its overall portfolio holdings.
Number of Shares
158,992
Previous 74,789
112.59%
Holding current value
$190,790
Previous $126,000
46.03%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding ENLV
# of Institutions
29Shares Held
3.43MCall Options Held
11.8KPut Options Held
9.1K-
Armistice Capital, LLC New York, NY2.21MShares$2.65 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny634KShares$760,6160.0% of portfolio
-
Morgan Stanley New York, NY270KShares$323,5860.0% of portfolio
-
Sigma Investment Counselors Inc28KShares$33,6000.0% of portfolio
-
Two Sigma Securities, LLC New York, NY22.4KShares$26,8340.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $22.1M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...